Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

The article highlights various financial dynamics within the pharmaceutical industry amid prevailing economic conditions.

Merck & Co., Inc. (MRK) is currently at $82.84, up $3.00 or 3.76% --Would be highest close since April 3, 2025, when it closed at $86.39 --On pace for largest percent increase since March 27, 2024, ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

AbbVie is now pushing Skyrizi and Rinvoq to counter the drop in Humira sales and has forecast the two newer drugs to generate ...

Scores of FDA employees are searching for an exit from an agency in turmoil, especially staffers tasked with reviewing drug ...